$0.03
(Market cap
$1,177 Mln
Recently Viewed
Clear AllMarket cap
$1,177 Mln
Revenue (TTM)
$39 Mln
P/E Ratio
--
P/B Ratio
2.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-16.4 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-1.3
Debt to Equity
--
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
207,647,924
CFO
€-328.01 Mln
EBITDA
€-347.07 Mln
Net Profit
€-350.39 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Inventiva Sa (IVA)
| 13.5 | -8.7 | -25.2 | 37.9 | 25.7 | -16.8 | -- |
|
BSE Sensex
| -8.3 | 4.2 | -5.6 | -2.4 | 9.2 | 10.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Inventiva Sa (IVA)
| 117.3 | -52.3 | 1.3 | -67.3 | -5.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Inventiva Sa (IVA)
|
5.3 | 1,177.4 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 2.1 |
| 22.8 | 12,698.2 | 19,628.0 | 978.0 | 9.1 | 6.8 | 11.5 | 0.8 | |
| 28.9 | 1,966.4 | 1,112.2 | 320.9 | -17.8 | 10.5 | 5.1 | 0.5 | |
| 1.5 | 155.8 | 2.8 | -47.2 | -86.4 | 734.6 | -- | 20.1 | |
| 34.0 | 1,638.7 | 29.6 | -24.0 | -- | 31.9 | -- | 65.0 | |
| 5.3 | 535.3 | 174.7 | -115.2 | 0.0 | -80.2 | -- | 4.1 |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The... company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France. Read more
Co-Founder, Chief Scientific Officer, Deputy CEO & Director
Dr. Pierre Broqua Ph.D.
Co-Founder, Chief Scientific Officer, Deputy CEO & Director
Dr. Pierre Broqua Ph.D.
Headquarters
Daix
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Inventiva Sa (IVA) is $5.28 (NASDAQ) as of 23-Apr-2026 12:39 EDT. Inventiva Sa (IVA) has given a return of 25.68% in the last 3 years.
Since, TTM earnings of Inventiva Sa (IVA) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Inventiva Sa (IVA) are Rs 7.98 and Rs 2.85 as of 23-Apr-2026.
Inventiva Sa (IVA) has a market capitalisation of $ 1,177 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Inventiva Sa (IVA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.